Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Hemoglobinopathies Market size was over USD 5.1 billion in 2024 and is estimated to reach USD 9.7 billion by the end of 2037, expanding at a CAGR of 5.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of hemoglobinopathies is assessed at USD 5.3 billion.
Despite being one of the rare blood disorders, this condition is still becoming a public health concern worldwide, which is boosting innovation and the widespread of the hemoglobinopathies market. Resource-constraint regions such as Africa, Asia, and the Mediterranean are witnessing significant growth in incidences, pushing the individual governing authorities to accommodate their healthcare system with adequate treatment, diagnosis, and prevention. According to a report from World Hemoglobinopathy Foundation, published in September 2023, the annual occurrence of this genetic hematology disorder among newborns ranged between 300,000 and 500,000 globally. Moreover, its negative impact and severity on the next generation is accumulating the focus of medical organizations from across the world.
With the proven efficacy of early detection in reducing prevalence and disease intensity, the hemoglobinopathies market is gaining traction with its advanced diagnostic solutions. The risk of developing this condition during pregnancy is affecting the reproductive chain of the global population severely. On this note, an NLM study, published in September 2022, revealed that such genetic disorders of hemoglobin impacted the fetus' health in around 7.0% of pregnancies worldwide. It also stated that over 90.0% of the incidences in newborns occur in middle- or low-income countries (LMICs). This showcases the importance of spreading awareness among couples to undergo precise prenatal diagnostic procedures available in this sector.
In addition to that, AI-powered drug development and large-scale manufacturing have notably increased accessibility in the therapeutics from the hemoglobinopathies market. According to a report released in the NLM Journal, in July 2024, the average costs of goods sold (COGS) for monoclonal antibodies (mAbs) dropped to USD 100.0/g or less in 2024 in LMICs, from USD 300.0/g in 2000. The very large scale (VLS) production of highly productive mAbs also presented a reduced COGS to USD 50.0/g for bulk drug substance in the same scenario. Thus, the efforts from different regions, particularly in Southeast Asia and Africa, are establishing a standard for payers’ pricing by improving affordability and availability.
Hemoglobinopathies Sector: Growth Drivers and Challenges
Growth Drivers
- Growing activities to spread awareness: Several promotional events conducted by both public and private organizations are propelling adoption in the hemoglobinopathies market. As more people and healthcare professionals gain knowledge from screening programs and educational campaigns, the consumer base widens. Following this approach, in a Cabinet meeting of Madhya Pradesh Mantralaya, held in July 2022, commenced a Hemoglobinopathy Diagnosis Programme. The new scheme enabled genetic counselling, community level screening, and investments in all 89 tribal development blocks to reduce mortality and morbidity from sickle cell anemia and thalassemia. Such initiatives empower the commercial assets of this field.
- Improvement in the effectiveness of therapies: Besides the advancements in detection methods, the improved actions of therapeutics from the hemoglobinopathies market have also gained traction. The introduction of gene therapies and genetic engineering has notably revolutionized patient outcomes. For instance, in June 2023, Vertex Pharmaceuticals, in collaboration with CRISPR, revealed promising results of pivotal trials, evaluating the efficacies of Cas9 gene-edited cell therapy. The results were showcased at the Annual European Hematology Association (EHA) Congress, presenting long-acting benefits and enhanced safety profile while treating transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).
Challenges
- Complexity and disparity in accessibility: The complex operations of the treatments from the hemoglobinopathies market are a major restriction in wide implementation. As these therapies are still at a developmental stage, full-fledged distribution may contain difficulty, particularly in rural or underserved regions. In addition, a shortage of specialized medical infrastructure and trained professionals may create an unavoidable hurdle in achieving optimum reach. Further, limited access to early detection and intervention may impact the effectiveness of these solutions, neutralizing consumers and investors’ interest.
- Long-term economic exhaustion: The economic gap between the service providers and consumers may hinder the expansion of the hemoglobinopathies market. Being in an experimental stage, many of the advanced therapies are still unachievable for patients with limited budgets. They may not be able to stretch their resources and patience to wait for the elongated results, preventing them from witnessing the complete potential of these curatives. Thus, the financial burden is a significant challenge in streamlining newer treatments, shrinking the scope of development due to lack of return-on-investments and consumer acceptance.
Hemoglobinopathies Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.5% |
|
Base Year Market Size (2024) |
USD 5.1 billion |
|
Forecast Year Market Size (2037) |
USD 9.7 billion |
|
Regional Scope |
|
Hemoglobinopathies Segmentation
Type (Thalassemia, Sickle Cell Disease, Others)
Based on type, the thalassemia segment is projected to dominate hemoglobinopathies market share of over 48.6% by 2037. This type of hemoglobin abnormality is the most common among other sub-types. A 2021 NLM study on global epidemiology of this disease revealed a notable increment in age-standardized mortality rates (ASMR), in comparison to 2019. It also showcased a considerable growth in age-standardized prevalence rates (ASPR) from 2018 to 2021. This testifies to the reason behind the segment’s predominant position. The genetic variation and severity levels of this condition are also prioritized by health institutions and pharmacology leaders due to the urgent need for disease identification and management.
Age-standardized Representation of Global Burden of Thalassemia (2021)
|
Discipline |
Rate (per 100,000) |
|
Prevalence |
18.2 |
|
Incidence |
1.9 |
|
Mortality |
0.1 |
|
Disability-adjusted-life-years (DALYs) |
11.6 |
Source: NLM 2024
Therapy (Monoclonal Antibody Medication, ACE Inhibitors, Hydroxyurea, Others)
In terms of therapy, the monoclonal antibody (mAb) medication segment is projected to dominate the hemoglobinopathies market throughout the assessed timeframe. The ongoing shift of consumer preference toward targeted therapies is consecutively extending this segment’s reach. As per Research Nester estimations, the gene therapy industry is predicted to surpass USD 12.4 billion by 2025 and USD 122.2 billion by 2037, with an astonishing CAGR of 20.6%. The figures indicate a continuous enlargement of this category, attributable to sufficient clinical evidence and international recognition. For instance, in June 2020, the European Commission gave clearance to Bristol Myers Squibb and Acceleron Pharma for commercializing Reblozyl (luspatercept), treating adults with β-thalassemia.
Our in-depth analysis of the global hemoglobinopathies market includes the following segments:
|
Type |
|
|
Therapy |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportHemoglobinopathies Industry - Regional Synopsis
North America Market Analysis
North America in hemoglobinopathies market is likely to hold more than 39.1% revenue share by 2037. Amalgamation of different genes from Africa and Asia has heightened the risk of genetic mutation, creating a potentially large patient pool for this sector. The region is pledged with leveraged access to healthcare and rapid penetration of technological advances. It is also privileged with an emphasized utility of mAbs in crafting targeted therapies for patients. On this note, a Research Nester report stated that North America is expected to captivate the highest share of 37.0% in the gene therapy industry. This highlights the significance of this region as a global supplier and resource cultivator in this field.
The U.S. is notably affected with the frequent prevalence of sickle cell disease (SCD), which fosters a demanding consumer base for the hemoglobinopathies market. As per the CDC report, published in May 2024, the occurrence of SCD in the U.S. was registered to be 100,000. It further testified that 90.0% of these cases were originated from non-Hispanic Black or African American citizens, where the contribution of Hispanic or Latino habitats in this number ranged between 3.0% and 9.0%. Thus, the severe impact of this condition on the quality and longevity of these patients’ lives is pushing the government and private organizations to increase the availability of effective solutions.
Canada is augmenting the hemoglobinopathies market with continuous government support for genetic engineering and rare disease assessments. The popularity and importance of genome sequencing and data processing have significantly risen in developing targeted therapies for these hematological conditions. This is further fueled by local investors and producers, who heavily invest in this field. In addition, the impact of this disease on children is also forcing the government to offer financial backup for extensive research. For instance, in February 2024, the government of Canada allocated a fund of USD 20.0 million over five years to strengthen the domestic R&D network for pediatric rare diseases such as hemoglobinopathies.
APAC Market Statistics
Asia Pacific is predicted to register the fastest CAGR in the hemoglobinopathies market over the forecasted timeframe. The region is utilizing its capabilities in clinical R&D and precision medicine to introduce strong therapeutic candidates in this sector. More clinical innovations are being curated under the influence of government support from the emerging biopharmaceutical landscapes such as India and China. For instance, in March 2024, Akums Drugs and Pharmaceuticals Limited introduced an affordable alternative of other expensive medicines for SCD in children. The new indigenous hydroxyurea oral suspension is designed to provide an effective treatment at only 1.0% of the global pricing. These creations are increasing accessibility and purchase rate in this sector.
India is engaging its pharmaceutical excellence to advance in the hemoglobinopathies market to combat the widespread inherited hemoglobin abnormalities. As per an NLM article, released in September 2023, the share of this country in the global β-thalassemia burden was 25.0%, accounting for 100,000 cases nationwide. Such a predominant demographic makes India an attractive marketplace for both domestic and global pioneers. In addition, the country is also escalating its local production and drug-discovery pace with the favorable activities of governing bodies. For instance, in February 2023, the Ministry of Madhya Pradesh enacted the Integrated Centre for Hemophilia and Hemoglobinopathies to make treatment for SCD accessible in 22 Tribal Districts.
China is cultivating a reliable supply-demand chain for the hemoglobinopathies market, empowered by its strong emphasis on precision medicine. The country is fostering its large genome data as a national asset to support a well-managed governance over the utility of genetic editing technology. The recent achievements of this therapy in improving patient outcomes during hemoglobinopathies treatment efficiently conclude the country’s prosperous future in this field. The country is also proactively promoting pre-marital, neonatal, and prenatal screening for reducing the prevalence of such conditions, encouraging more consumers to invest in this sector.
Companies Dominating the Hemoglobinopathies Landscape
- Sangamo Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Global Blood Therapeutics, Inc.
- bluebird bio, Inc.
- Emmaus Life Sciences Inc.
- Pfizer, Inc.
- Novartis AG
- Prolong Pharmaceuticals, LLC
- Bioverativ Inc.
- Gamida Cell
- Celgene Corporation
- YolTech Therapeutics
- Devyser
- Agios Pharmaceuticals, Inc.
Continuous innovations in the hemoglobinopathies market, supervised by global biotech leaders and pharma pioneers, are diversifying the range of options. This is resulting in wide adoption and increased availability in this sector. For instance, in August 2022, bluebird bio earned FDA clearance for its ZYNTEGLO (betibeglogene autotemcel) to treat adult and pediatric β-thalassemia residents, undergoing red blood cell (RBC) transfusions on a daily basis. The drug is specifically formulated to target the root genetic cause of the disease to offer a long-acting relief to the patient. Such groundbreaking therapeutics are evidence of a progressive trading atmosphere, attracting more participants. Such key players are:
In the News
- In February 2025, Devyser launched a next-generation sequencing (NGS) solution, Devyser Thalassemia v2, to enhance thalassemia detection with improved precision. The technology helps streamline and widen screening for researchers with faster and more consistent outcomes.
- In January 2025, YolTech Therapeutics commenced clinical trials for its new investigational therapy, YOLT-204. The first-in-class in vivo gene editing therapy has the potential to treat transfusion-dependent beta-thalassemia (TDT), extending its lipid nanoparticles (LNP) pipeline.
- In June 2024, Agios Pharmaceuticals revealed the promising results from the global phase III ENERGIZE-T study on mitapivat. The statistics showcased a significant reduction in the need for blood transfusion while offering treatment for both alpha- or beta-thalassemia.
Author Credits: Radhika Pawar
- Report ID: 7255
- Published Date: Mar 03, 2025
- Report Format: PDF, PPT
